 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Reporting Positive Data on Conjugate Delivery Tech, Alnylam Preps IND for Subcutaneous ATTR Therapy
August 09, 2012
Reporting Positive Data on Conjugate Delivery Tech, Alnylam Preps IND for Subcutaneous ATTR Therapy
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira on Track to Move Cancer Drug into Phase II, Name New Clinical Candidate in ‘13
May 16, 2013 / Gene Silencing News - Alnylam Starts Phase I Trial of Subcutaneous ATTR Drug
March 21, 2013 / Gene Silencing News - Alnylam Loses Cubist as RSV Partner, Stays Focused on ATTR Programs
February 14, 2013 / Gene Silencing News - Alnylam, Tekmira Shares Regain Lost Ground Heading into 2013
January 24, 2013 / Gene Silencing News - Alnylam to Sell $125M in Stock
January 17, 2013 / Gene Silencing News